Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 18, 2017
BioLife Solutions to Present at Upcoming Investor Conferences
BOTHELL, Wash., Oct. 18, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic ...
October 18, 2017
FDA Advisory Committee Scheduled to Review TLANDO™ on January 10, 2018
SALT LAKE CITY, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) ...
October 17, 2017
Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B
STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News: Transgene (TNG.PA) (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, will be presenting a poster on TG1050 first ...
October 17, 2017
STRATA Skin Sciences Announces Agreement with MedResults Network, a GPO Exclusive to the Aesthetic Medical Market
HORSHAM, Pa., Oct. 17, 2017 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to ...
October 17, 2017
Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm
PARIS, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO) (FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development ...
October 17, 2017
Pernix Therapeutics Announces Planned Departure of Chief Financial Officer
MORRISTOWN, N.J., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that Graham ...
October 17, 2017
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017
VANCOUVER, Oct. 16, 2017 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...
October 17, 2017
Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors
SAN DIEGO--(BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the European Medicines Agency (EMA) has granted Priority Medicines ...
October 17, 2017
BrainStorm Announces Third Quarter 2017 Financial Results
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 17, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapies for ...
October 17, 2017
VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017
CAMBRIDGE, MASSACHUSETTS -- (Marketwired - Oct 17, 2017) -- VBI Vaccines Inc. (VBIV)(VBV.TO) (VBI) today announced the company's abstract, "Antibody and Cell-mediated Immunity against PreS1, ...
October 13, 2017
Transgene: Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors
STRASBOURG, France -- (BUSINESS WIRE) -- Regulatory News: Transgene (TNG.PA), a biotech company that designs and develops viral-based immunotherapies, recently published two papers supporting the efficacy and ...
October 13, 2017
Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients
SAN DIEGO, Oct. 12, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage oncology biotechnology company, announced today that the Company has been included in ...
October 13, 2017
Prometic Announces FDA Acceptance of its Biologics License Application for Plasminogen (Ryplazim™)
LAVAL, QC, Oct. 13, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced that the U.S Food and Drug Administration (FDA) has accepted ...
October 13, 2017
Rexahn Announces $8 Million Registered Direct Offering
ROCKVILLE, Md., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN) today announced it has entered into definitive agreements with institutional investors to ...
October 13, 2017
BioTime, Inc. Announces Pricing of $25.0 Million Public Offering of Common Stock
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative ...
October 12, 2017
BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva
RALEIGH, N.C., Oct. 12, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, ...
October 12, 2017
Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide
Copenhagen, Denmark, October 12, 2017 - Zealand Pharma announces dosing has started in a clinical trial with glepaglutide under an investigational new drug application (IND) ...
October 12, 2017
Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
October 12, 2017
Acer Therapeutics Welcomes Two New Members to its Board of Directors
CAMBRIDGE, Mass., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc., (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
October 11, 2017
BIOPHYTIS completes a €10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates
PARIS, Oct. 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, ...
Page 132 of 162